fcn-338 + erythromycin + cytarabine

This is a combination of three drugs: - **FCN-338**: a novel, potent, and selective small molecule inhibitor of B-cell lymphoma-2 (Bcl-2), targeting the anti-apoptotic pathway. Developed primarily for hematologic malignancies, FCN-338 works by inhibiting Bcl-2, thus triggering apoptosis in Bcl-2-dependent cancer cells. It shows high affinity for Bcl-2 and less for Bcl-xL, potentially lowering the risk of thrombocytopenia compared to other Bcl-2 inhibitors. Its main indications are chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and other B-cell lymphomas[1][2][3][5]. - **Erythromycin**: a well-established macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, most commonly used to treat respiratory tract, skin, and soft tissue infections. It is not primarily used in cancer therapy. - **Cytarabine**: a cytotoxic chemotherapy drug (antimetabolite) that inhibits DNA synthesis, commonly used for the treatment of leukemias such as acute myeloid leukemia (AML) and some lymphomas. It acts during the S-phase of the cell cycle[5]. No unique clinical product or combination under this name is marketed, but combinations of Bcl-2 inhibitors with chemotherapy agents like cytarabine are frequently studied in clinical trials for hematological malignancies. There is evidence that FCN-338 is being studied in combination with chemotherapies in myeloid neoplasms (including cytarabine), though erythromycin is not established as a standard oncology combinatorial agent[3][5].